Abstract BACKGROUND Tau pathology in Alzheimer's disease (AD) propagates along the brain's connectome, yet the mechanisms by which tau drives neuronal dysfunction remain unclear. We hypothesized that dysfunction primarily emerges in regions close to tau‐harboring epicenters. METHODS One hundred thirty‐one amyloid‐posit...
Lukas Frontzkowski, Sebastian N. Roemer-Cassiano, Johannes S. Gnörich et al.· Alzheimer's & Dementia· 0 citations
Dynamic [18F]PI-2620 PET imaging facilitates assessment of the β-amyloid status and regional staging of tau and neurodegeneration during a single acquisition, and may reduce radiation exposure, streamline diagnostic workflows, and facilitate personalized disease profiling.
Johannes S. Gnörich, J. Kusche-Palenga, Agnes Kling et al.· Molecular Neurodegeneration· 0 citations
In CSF-confirmed participants, age emerged as the most consistent predictor of plasma biomarker levels, particularly NFL and pTau181, which suggests that plasma biomarkers are influenced primarily by age and genetic background rather than by metabolic factors in this cohort.
Carolin I. Kurz, Marleen Taute, Paulina Tegethoff et al.· Aging Brain· 0 citations
WMH confluence is introduced as a reproducible, automated, and fine-grained measure of lesion spatial organisation that provides complementary information about morphological WMH severity beyond volume and is an alternative to visual rating scales.
Tatjana Schmidt, Robert Salzmann, M. Montagnese et al.· bioRxiv· 0 citations
BAG is a reliable non-invasive marker of structural brain health sensitive to AD pathology and to modifiable AD risk and supports its relevance for early risk stratification and prevention-oriented research.
E. Kuhn, G. Antopoulos, L. Kleineidam et al.· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
